Substantial statistical heterogeneity among eligible studies (I2 > 50%) was observed in most of the analyses, except for the overall discordance rate of PIK3CA mutational status from mutated to wild-type and the HER2 + and triple-negative breast cancer (TNBC) subgroup analyses. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.